Johnson & Johnson $JNJ Stock Holdings Trimmed by Cladis Investment Advisory LLC

Cladis Investment Advisory LLC lowered its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.9% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,649 shares of the company’s stock after selling 149 shares during the period. Cladis Investment Advisory LLC’s holdings in Johnson & Johnson were worth $605,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. Elios Financial Group Inc. raised its stake in shares of Johnson & Johnson by 1.5% in the 1st quarter. Elios Financial Group Inc. now owns 4,496 shares of the company’s stock worth $746,000 after buying an additional 66 shares in the last quarter. Atlantic Family Wealth LLC raised its stake in shares of Johnson & Johnson by 4.4% in the 1st quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company’s stock worth $266,000 after buying an additional 67 shares in the last quarter. MBA Advisors LLC raised its stake in shares of Johnson & Johnson by 1.2% in the 1st quarter. MBA Advisors LLC now owns 5,553 shares of the company’s stock worth $921,000 after buying an additional 68 shares in the last quarter. Sovereign Financial Group Inc. raised its stake in shares of Johnson & Johnson by 1.8% in the 1st quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company’s stock worth $651,000 after buying an additional 69 shares in the last quarter. Finally, Nabity Jensen Investment Management Inc raised its stake in shares of Johnson & Johnson by 1.5% in the 1st quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company’s stock worth $767,000 after buying an additional 69 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the topic of a number of recent analyst reports. Guggenheim reaffirmed a “neutral” rating and set a $167.00 target price (up from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Leerink Partnrs lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 13th. Wall Street Zen downgraded Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Friday, July 18th. UBS Group lifted their price target on Johnson & Johnson from $180.00 to $190.00 and gave the company a “buy” rating in a report on Thursday, July 17th. Finally, Barclays lifted their price target on Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a report on Thursday, July 17th. Nine analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $174.50.

Johnson & Johnson Stock Performance

JNJ opened at $176.76 on Monday. The company has a market cap of $425.70 billion, a PE ratio of 18.90, a price-to-earnings-growth ratio of 2.25 and a beta of 0.41. The stock has a 50-day moving average of $161.28 and a 200-day moving average of $158.43. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $177.27. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The firm’s revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.82 EPS. As a group, equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.